Indiana Trust & Investment Management CO Purchases 132 Shares of Becton, Dickinson and Company (NYSE:BDX)

Indiana Trust & Investment Management CO grew its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 126.9% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 236 shares of the medical instruments supplier’s stock after purchasing an additional 132 shares during the quarter. Indiana Trust & Investment Management CO’s holdings in Becton, Dickinson and Company were worth $58,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of BDX. Norges Bank bought a new stake in Becton, Dickinson and Company during the 4th quarter valued at $761,798,000. Vanguard Group Inc. lifted its holdings in Becton, Dickinson and Company by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock worth $6,703,041,000 after purchasing an additional 516,427 shares in the last quarter. Royal Bank of Canada lifted its stake in Becton, Dickinson and Company by 28.5% in the 3rd quarter. Royal Bank of Canada now owns 2,139,493 shares of the medical instruments supplier’s stock worth $553,121,000 after purchasing an additional 473,914 shares in the last quarter. Morgan Stanley boosted its holdings in Becton, Dickinson and Company by 4.5% in the 3rd quarter. Morgan Stanley now owns 10,200,213 shares of the medical instruments supplier’s stock valued at $2,637,062,000 after purchasing an additional 435,168 shares during the period. Finally, Cooke & Bieler LP grew its position in shares of Becton, Dickinson and Company by 117.1% during the 4th quarter. Cooke & Bieler LP now owns 710,932 shares of the medical instruments supplier’s stock valued at $173,347,000 after purchasing an additional 383,485 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Up 1.2 %

Shares of BDX opened at $233.71 on Friday. Becton, Dickinson and Company has a 1 year low of $224.00 and a 1 year high of $287.32. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.41 and a quick ratio of 0.97. The stock has a 50 day simple moving average of $234.36 and a two-hundred day simple moving average of $237.84. The firm has a market cap of $67.54 billion, a P/E ratio of 51.48, a P/E/G ratio of 2.03 and a beta of 0.44.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.97 by $0.20. The company had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The firm’s revenue was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.86 EPS. On average, analysts forecast that Becton, Dickinson and Company will post 13.04 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 28th. Stockholders of record on Monday, June 10th were paid a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.63%. The ex-dividend date of this dividend was Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Analyst Ratings Changes

BDX has been the subject of several research analyst reports. StockNews.com lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Thursday. Barclays lifted their price target on Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research report on Monday, May 6th. Finally, The Goldman Sachs Group started coverage on shares of Becton, Dickinson and Company in a research report on Thursday, May 30th. They issued a “buy” rating and a $274.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $280.17.

Insider Buying and Selling

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $239.31, for a total value of $71,793.00. Following the completion of the sale, the senior vice president now owns 1,976 shares in the company, valued at $472,876.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Michael David Garrison sold 1,715 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total value of $399,269.15. Following the sale, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at $1,252,750.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Thomas J. Spoerel sold 300 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $239.31, for a total value of $71,793.00. Following the transaction, the senior vice president now directly owns 1,976 shares of the company’s stock, valued at approximately $472,876.56. The disclosure for this sale can be found here. Insiders have sold a total of 8,615 shares of company stock worth $2,033,381 in the last ninety days. 0.31% of the stock is owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.